Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S3050597626000308?dgcid=rss_sd_all
Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S3050597626000308?dgcid=rss_sd_all
“Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era.” Blood Immunology & Cellular Therapy.
@article{article38488,
title = {Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S3050597626000308?dgcid=rss_sd_all}
}